Literature DB >> 23179192

The treatment of systemic lupus proliferative nephritis.

Marilynn G Punaro1.   

Abstract

Lupus nephritis is one of the most common and serious complications of systemic lupus erythematosus (SLE) in childhood affecting more than 80% of patients. Treatment of this complication has undergone significant evolution in recent years. A series of randomized controlled trials has clarified the role of a variety of immunomodulating regimens including some novel biologic medications. This review touches on the major trials that have influenced practice and shaped current thinking about the treatment of proliferative lupus glomerulonephritis.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23179192     DOI： 10.1007/s00467-012-2327-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  51 in total

1.  Sequential therapies for proliferative lupus nephritis.

Authors:  Gabriel Contreras; Victoriano Pardo; Baudouin Leclercq; Oliver Lenz; Elaine Tozman; Patricia O'Nan; David Roth
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

2.  Pediatric rheumatic disease: Treating lupus nephritis in children--is there a gold standard?

Authors:  Rolando Cimaz
Journal:  Nat Rev Rheumatol       Date:  2012-02-28       Impact factor: 20.543

3.  Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.

Authors:  Tak-Mao Chan; Kai-Chung Tse; Colin Siu-On Tang; Mo-Yin Mok; Fu-Keung Li
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

4.  Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage.

Authors:  Hermine I Brunner; Earl D Silverman; Theresa To; Claire Bombardier; Brian M Feldman
Journal:  Arthritis Rheum       Date:  2002-02

5.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Authors:  Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons
Journal:  N Engl J Med       Date:  2011-11-17       Impact factor: 91.245

6.  A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; S P Lan; R D Rohde; J M Lachin
Journal:  N Engl J Med       Date:  1992-05-21       Impact factor: 91.245

7.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

8.  Accrual of organ damage over time in patients with systemic lupus erythematosus.

Authors:  Dafna D Gladman; Murray B Urowitz; Proton Rahman; Dominique Ibañez; Lai-Shan Tam
Journal:  J Rheumatol       Date:  2003-09       Impact factor: 4.666

9.  Clinical-pathological features and prognosis of thrombotic thrombocytopenic purpura in patients with lupus nephritis.

Authors:  Tang Zheng; Luo Chunlei; Wang Zhen; Liu Ping; Zhang Haitao; Hu Weixin; Zeng Caihong; Chen Huiping; Liu Zhihong; Li Leishi
Journal:  Am J Med Sci       Date:  2009-11       Impact factor: 2.378

10.  Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Authors:  Frédéric A Houssiau; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Radmila Petrovic; Christoph Fiehn; Enrique de Ramon Garrido; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2010-09-10       Impact factor: 19.103
View more
  5 in total

Review 1.  The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved.

Authors:  Ole Petter Rekvig; Johan Van der Vlag
Journal:  Semin Immunopathol       Date:  2014-04-25       Impact factor: 9.623

2.  Long-term renal outcomes of childhood-onset global and segmental diffuse proliferative lupus nephritis.

Authors:  Pornpimol Rianthavorn; Athitaya Buddhasri
Journal:  Pediatr Nephrol       Date:  2015-06-09       Impact factor: 3.714

Review 3.  Effect of mycophenolic acid in experimental, nontransplant glomerular diseases: new mechanisms beyond immune cells.

Authors:  Agnes Hackl; Rasmus Ehren; Lutz Thorsten Weber
Journal:  Pediatr Nephrol       Date:  2016-06-16       Impact factor: 3.714

Review 4.  Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses.

Authors:  Yuehong Chen; Jianhong Sun; Kun Zou; Yuan Yang; Gang Liu
Journal:  Rheumatol Int       Date:  2017-05-10       Impact factor: 3.580

5.  The impact of antiphospholipid antibodies in children with lupus nephritis.

Authors:  Sulaiman M Al-Mayouf; Alhanouf AlSaleem; Turki Al-Hussain; Abdullah Al Sonbul; Hadeel AlMana
Journal:  Int J Pediatr Adolesc Med       Date:  2015-11-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.